Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes | TR-130 | 142-04-1 | Aniline hydrochloride | Rats | F344/N | Male | Dosed-Feed | Vascular System (Spleen) | Positive | Positive | HEMANGIOSARCOMA; SARCOMA OR FIBROSARCOMA | Neoplastic Lesions |
Yes | TR-351 | 20265-96-7 | p-Chloroaniline hydrochloride | Mice | B6C3F1 | Male | Gavage | Vascular System (Spleen) | Some Evidence | Some Evidence | HEMANGIOSARCOMA 3/50 2/47 0/49 5/49 | Neoplastic Lesions |
Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Vascular System (Spleen) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50 | Neoplastic Lesions |
Yes | TR-349 | 87-86-5 | Pentachlorophenol, Dowicide EC-7 | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Spleen) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/34 0/50 2/50 2/47 | Neoplastic Lesions |
Yes | TR-349 | 87-86-5 | Pentachlorophenol, technical | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Spleen) | Some Evidence | Some Evidence | HEMANGIOSARCOMA 0/33 1/50 3/47 | Neoplastic Lesions |
Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
---|---|---|---|---|---|---|---|---|---|---|---|---|
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 4/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/50 4/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Liver | Clear Evidence | Clear Evidence | ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50 | May Have Been Related |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/50 5/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | 0/50 1/50 4/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Nasal Cavity | Clear Evidence | Clear Evidence | ADENOMA 0/50 44/50 49/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Nasal Cavity | Clear Evidence | Clear Evidence | ADENOMA 0/50 48/50 48/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50 | Neoplastic Lesions |
Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Vascular System (Spleen) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50 | Neoplastic Lesions |
No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50 | Neoplastic Lesions |
No | TR-130 | 142-04-1 | Aniline hydrochloride | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
No | TR-130 | 142-04-1 | Aniline hydrochloride | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
No | TR-130 | 142-04-1 | Aniline hydrochloride | Rats | F344/N | Female | Dosed-Feed | Spleen | Positive | Positive | SARCOMA | Neoplastic Lesions |
Yes | TR-130 | 142-04-1 | Aniline hydrochloride | Rats | F344/N | Male | Dosed-Feed | Vascular System (Spleen) | Positive | Positive | HEMANGIOSARCOMA; SARCOMA OR FIBROSARCOMA | Neoplastic Lesions |
No | TR-351 | 20265-96-7 | p-Chloroaniline hydrochloride | Mice | B6C3F1 | Female | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
No | TR-351 | 20265-96-7 | p-Chloroaniline hydrochloride | Rats | F344/N | Male | Gavage | Adrenal Gland Medulla | Clear Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 13/49 14/48 15/48 26/49 | May Have Been Related |
No | TR-351 | 20265-96-7 | p-Chloroaniline hydrochloride | Rats | F344/N | Female | Gavage | Adrenal Gland Medulla | Equivocal Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 2/50 3/50 1/50 6/50 | Neoplastic Lesions |
No | TR-351 | 20265-96-7 | p-Chloroaniline hydrochloride | Mice | B6C3F1 | Male | Gavage | Liver | Some Evidence | Some Evidence | ADENOMA 9/50 15/49 10/50 44/50 OR CARCINOMA 3/50 7/49 11/50 17/50 COMBINED 11/50 21/49 20/50 21/50 | Neoplastic Lesions |
No | TR-351 | 20265-96-7 | p-Chloroaniline hydrochloride | Rats | F344/N | Male | Gavage | Spleen | Clear Evidence | Clear Evidence | FIBROSARCOMA 0/49 1/50 2/50 17/50, HEMANGIOSARCOMA 0/49 0/50 0/50 4/50, OR OSTEOSARCOMA 0/49 0/50 1/50 19/50 COMBINED 0/49 1/50 3/50 38/50 | Neoplastic Lesions |
No | TR-351 | 20265-96-7 | p-Chloroaniline hydrochloride | Rats | F344/N | Female | Gavage | Spleen | Equivocal Evidence | Equivocal Evidence | FIBROSARCOMA 0/50 0/50 1/50 0/50 OR OSTEOSARCOMA 0/50 0/50 0/50 1/50 COMBINED 0/50 0/50 1/50 1/50 | Neoplastic Lesions |
No | TR-351 | 20265-96-7 | p-Chloroaniline hydrochloride | Mice | B6C3F1 | Male | Gavage | Vascular System (Liver) | Some Evidence | Some Evidence | HEMANGIOSARCOMA 2/50 2/50 1/49 6/50 | Neoplastic Lesions |
Yes | TR-351 | 20265-96-7 | p-Chloroaniline hydrochloride | Mice | B6C3F1 | Male | Gavage | Vascular System (Spleen) | Some Evidence | Some Evidence | HEMANGIOSARCOMA 3/50 2/47 0/49 5/49 | Neoplastic Lesions |
No | TR-349 | 87-86-5 | Pentachlorophenol, Dowicide EC-7 | Mice | B6C3F1 | Female | Dosed-Feed | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | PHEOCHROMOCYTOMA 0/35 2/49 2/46 38/49 | Neoplastic Lesions |
No | TR-349 | 87-86-5 | Pentachlorophenol, Dowicide EC-7 | Mice | B6C3F1 | Male | Dosed-Feed | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | PHEOCHROMOCYTOMA 0/34 4/48 21/48 44/49 OR MALIGNANT PHEOCHROMOCYTOMA 1/34 0/48 0/48 3/49 COMBINED 1/34 4/48 21/48 45/49 | Neoplastic Lesions |
No | TR-349 | 87-86-5 | Pentachlorophenol, Dowicide EC-7 | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 1/34 3/50 6/49 30/48 OR CARCINOMA 0/34 1/50 0/49 1/48 COMBINED 1/34 4/50 6/49 31/48 | Neoplastic Lesions |
No | TR-349 | 87-86-5 | Pentachlorophenol, Dowicide EC-7 | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 5/35 13/48 17/48 32/49 OR CARCINOMA 1/35 7/48 7/48 9/49 COMBINED 6/35 19/48 21/48 34/49 | Neoplastic Lesions |
No | TR-349 | 87-86-5 | Pentachlorophenol, Dowicide EC-7 | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Liver) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/34 1/50 1/49 8/48 | Neoplastic Lesions |
Yes | TR-349 | 87-86-5 | Pentachlorophenol, Dowicide EC-7 | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Spleen) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/34 0/50 2/50 2/47 | Neoplastic Lesions |
No | TR-349 | 87-86-5 | Pentachlorophenol, technical | Mice | B6C3F1 | Male | Dosed-Feed | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | PHEOCHROMOCYTOMA 0/31 10/45 23/45 | Neoplastic Lesions |
No | TR-349 | 87-86-5 | Pentachlorophenol, technical | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 5/32 20/47 33/48 OR CARCINOMA 2/32 10/47 12/48 COMBINED 7/32 26/47 37/48 | Neoplastic Lesions |
No | TR-349 | 87-86-5 | Pentachlorophenol, technical | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Some Evidence | Some Evidence | ADENOMA 3/33 8/49 8/50 OR CARCINOMA 0/33 1/49 1/50 COMBINED 3/33 9/49 9/50 | Neoplastic Lesions |
No | TR-349 | 87-86-5 | Pentachlorophenol, technical | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Liver) | Some Evidence | Some Evidence | HEMANGIOSARCOMA 0/33 2/49 4/50 | Neoplastic Lesions |
Yes | TR-349 | 87-86-5 | Pentachlorophenol, technical | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Spleen) | Some Evidence | Some Evidence | HEMANGIOSARCOMA 0/33 1/50 3/47 | Neoplastic Lesions |